A Legislative History of the Federal Food, Drug, and Cosmetic Act and Its Amendments: TextU.S. Department of Health, Education, and Welfare, Public Health Service, Food and Drug Administration, 1979 - Cosmetics |
From inside the book
Results 1-5 of 54
Page 88
... discovery of counterfeit drugs here in Washington , D.C. , and in Baltimore are but a few examples of a vicious practice spreading throughout the United States . Mr. President , we cannot allow unscrupulous men to pile up profits at the ...
... discovery of counterfeit drugs here in Washington , D.C. , and in Baltimore are but a few examples of a vicious practice spreading throughout the United States . Mr. President , we cannot allow unscrupulous men to pile up profits at the ...
Page 113
... discovery patented in this country . The MMSA defended its buying abroad on the grounds that by buying the cheap foreign drugs it could help drive down what it considered too high American prices . It justified its disregard of Amer ...
... discovery patented in this country . The MMSA defended its buying abroad on the grounds that by buying the cheap foreign drugs it could help drive down what it considered too high American prices . It justified its disregard of Amer ...
Page 148
... discovery reveals that drug discoveries in foreign countries without product patents out- number those in countries with patent protection by 10 to 1 . Furthermore , we should see that pat- ent monopolies of drugs , vital to the public ...
... discovery reveals that drug discoveries in foreign countries without product patents out- number those in countries with patent protection by 10 to 1 . Furthermore , we should see that pat- ent monopolies of drugs , vital to the public ...
Page 181
... discovery in individual product groups ... Corticosteroids ... 120 121 Tranquilizers .... 121 Oral antidiabetics .. 123 Antibiotics ... 123 Basic research versus product development . Chapter 8. Patents and restriction of competition ...
... discovery in individual product groups ... Corticosteroids ... 120 121 Tranquilizers .... 121 Oral antidiabetics .. 123 Antibiotics ... 123 Basic research versus product development . Chapter 8. Patents and restriction of competition ...
Page 184
... discovery .. Table 39. Examples of foreign discoveries in countries without product patents .... Research and development : steps , activities , and promises for the future .. Table 40. Nobel Prize winners in medicine and physiology ...
... discovery .. Table 39. Examples of foreign discoveries in countries without product patents .... Research and development : steps , activities , and promises for the future .. Table 40. Nobel Prize winners in medicine and physiology ...
Other editions - View all
Common terms and phrases
ADMINISTERED PRICES ADMINISTERED PRICES-DRUGS advertising amended American Cyanamid American Home Products antibiotics Antitrust Antitrust and Monopoly appear application Association Aureomycin bill bottle brand name Bristol capsules Carter cents chart chemical chloramphenicol Chloromycetin chlorpromazine chlorpropamide Committee competition Corp corticosteroids cortisone Cosmetic countries Davis Decadron dexamethasone Diabinese discovery doctors Drug Administration drug companies drug industry drug manufacturers drug products efficacy erythromycin ethical drugs Federal firms Food and Drug foreign prices Hearings hospital Ibid insulin Journal Laboratories license Lilly margin medicine ment meprobamate Merck million MMSA National Office Orinase packaging Parke penicillin percent Pfizer pharmaceutical pharmacists pharmacy physician prednisolone prednisone prescribed prescription president Price to druggist prochlorperazine product patents production costs profit promotion reported retail royalty Schering Secretary selling Senator KEFAUVER side effects sold Squibb steroid subcommittee subsection Syntex Table tablets tetracycline thereof tion tolbutamide trade name United Upjohn
Popular passages
Page 475 - ... may obtain judicial review by filing in the United States court of appeals for the circuit wherein such person resides or has his principal place of business, or in the United States Court of Appeals for the District of Columbia Circuit, within sixty days after the entry of such order, a petition praying that the order be set aside in whole or in part.
Page 250 - That, as we enjoy great advantages from the inventions of others, we should be glad of an opportunity to serve others by any invention of ours; and this we should do freely and generously.
Page 475 - ... a petition with the United States court of appeals for the circuit wherein such person resides or has his principal place of business, for a judicial review of such order.
Page 475 - The judgment of the court affirming or setting aside, in whole or in part, any action of the Secretary shall be final, subject to review by the Supreme Court of the United States upon certiorari or certification as provided in section 1254 of Title 28, United States Code.
Page 447 - People of the same trade seldom meet together, even for merriment and diversion, but the conversation ends in a conspiracy against the public, or in some contrivance to raise prices.
Page 483 - Mr. President, I suggest the absence of a quorum. The PRESIDING OFFICER. The clerk will call the roll.
Page 12 - Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. The PRESIDING OFFICER. Without objection, it is so ordered.
Page 75 - Judiciary, or any duly authorized subcommittee thereof, is authorized under sections 134 (a) and 136 of the Legislative Reorganization Act of 1946, as amended, and in accordance with its jurisdictions specified by rule XXV of the Standing Rules of the Senate, to...
Page 476 - USC 1003). (d) After each such review, and at such other times as the Secretary may determine to be necessary or desirable, the Secretary shall cause to be compiled, published, and publicly distributed a list which shall list all revised official names of drugs designated under this section and shall contain such descriptive and explanatory matter as the Secretary may determine to be required for the effective use of those names.
Page 307 - CHLOROMYCETIN is a potent therapeutic agent and, because certain blood dyscrasias have been associated with its administration, it should not be used indiscriminately or for minor infections. Furthermore, as with certain other drugs, adequate blood studies should be made when the patient requires prolonged or intermittent therapy.